EXOZYMES INC (EXOZ) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:EXOZ • US4618741098

10.51 USD
-0.34 (-3.13%)
Last: Feb 6, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Taking everything into account, EXOZ scores 1 out of 10 in our fundamental rating. EXOZ was compared to 525 industry peers in the Biotechnology industry. The financial health of EXOZ is average, but there are quite some concerns on its profitability. EXOZ does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year EXOZ has reported negative net income.
  • EXOZ had a negative operating cash flow in the past year.
EXOZ Yearly Net Income VS EBIT VS OCF VS FCFEXOZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • EXOZ's Return On Assets of -108.04% is on the low side compared to the rest of the industry. EXOZ is outperformed by 76.34% of its industry peers.
  • EXOZ has a Return On Equity of -155.17%. This is in the lower half of the industry: EXOZ underperforms 64.31% of its industry peers.
Industry RankSector Rank
ROA -108.04%
ROE -155.17%
ROIC N/A
ROA(3y)-51.41%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EXOZ Yearly ROA, ROE, ROICEXOZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for EXOZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EXOZ Yearly Profit, Operating, Gross MarginsEXOZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • EXOZ has more shares outstanding than it did 1 year ago.
  • EXOZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EXOZ Yearly Shares OutstandingEXOZ Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M
EXOZ Yearly Total Debt VS Total AssetsEXOZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • An Altman-Z score of 16.78 indicates that EXOZ is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of EXOZ (16.78) is better than 88.36% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that EXOZ is not too dependend on debt financing.
  • EXOZ's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. EXOZ outperforms 44.66% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 16.78
ROIC/WACCN/A
WACCN/A
EXOZ Yearly LT Debt VS Equity VS FCFEXOZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

  • A Current Ratio of 4.53 indicates that EXOZ has no problem at all paying its short term obligations.
  • EXOZ has a Current ratio (4.53) which is comparable to the rest of the industry.
  • A Quick Ratio of 4.53 indicates that EXOZ has no problem at all paying its short term obligations.
  • EXOZ has a Quick ratio (4.53) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.53
Quick Ratio 4.53
EXOZ Yearly Current Assets VS Current LiabilitesEXOZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The earnings per share for EXOZ have decreased strongly by -256.10% in the last year.
EPS 1Y (TTM)-256.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • EXOZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EXOZ Price Earnings VS Forward Price EarningsEXOZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EXOZ Per share dataEXOZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • EXOZ does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EXOZYMES INC

NASDAQ:EXOZ (2/6/2026, 8:00:01 PM)

10.51

-0.34 (-3.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-31
Inst Owners0.71%
Inst Owner ChangeN/A
Ins Owners24.86%
Ins Owner Change0%
Market Cap88.18M
Revenue(TTM)N/A
Net Income(TTM)-8.34M
AnalystsN/A
Price TargetN/A
Short Float %0.42%
Short Ratio2.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 16.41
P/tB 16.41
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.26
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS0
BVpS0.64
TBVpS0.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -108.04%
ROE -155.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.41%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 108.26%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.53
Quick Ratio 4.53
Altman-Z 16.78
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)140.25%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-256.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.81%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-230.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-505.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-620.26%
OCF growth 3YN/A
OCF growth 5YN/A

EXOZYMES INC / EXOZ FAQ

What is the ChartMill fundamental rating of EXOZYMES INC (EXOZ) stock?

ChartMill assigns a fundamental rating of 1 / 10 to EXOZ.


What is the valuation status of EXOZYMES INC (EXOZ) stock?

ChartMill assigns a valuation rating of 0 / 10 to EXOZYMES INC (EXOZ). This can be considered as Overvalued.


What is the profitability of EXOZ stock?

EXOZYMES INC (EXOZ) has a profitability rating of 0 / 10.


Can you provide the financial health for EXOZ stock?

The financial health rating of EXOZYMES INC (EXOZ) is 5 / 10.